ImageneBio, Inc. (NASDAQ:IMA) Short Interest Update

ImageneBio, Inc. (NASDAQ:IMA) was the target of a significant drop in short interest in August. As of August 14th, there was short interest totaling 49,297 shares, a drop of 87.2% from the July 30th total of 384,525 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 9,956 shares, the short-interest ratio is presently 5.0 days.

ImageneBio Price Performance

Shares of NASDAQ:IMA traded up $0.01 during trading on Friday, reaching $5.34. 4,581 shares of the company’s stock traded hands, compared to its average volume of 146,566. The stock has a market capitalization of $60.61 million, a P/E ratio of -1.17 and a beta of 0.76. ImageneBio has a 12 month low of $3.94 and a 12 month high of $13.98. The company has a 50 day moving average of $5.77 and a 200-day moving average of $5.81.

ImageneBio (NASDAQ:IMA) last issued its earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.27. Equities research analysts predict that ImageneBio will post -3.23 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IMA has been the topic of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of ImageneBio in a research note on Monday, June 29th. HC Wainwright began coverage on ImageneBio in a research report on Friday, August 21st. They issued a “buy” rating and a $28.00 target price for the company. Wall Street Zen downgraded ImageneBio from a “sell” rating to a “strong sell” rating in a report on Sunday, May 17th. Finally, Wedbush reissued an “underperform” rating on shares of ImageneBio in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $29.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC acquired a new stake in ImageneBio in the second quarter worth $539,044,000. Trails Edge Capital Partners LP acquired a new position in shares of ImageneBio during the second quarter valued at $1,663,824,000. Hsbc Holdings PLC bought a new position in shares of ImageneBio during the second quarter worth about $208,000. Cable Car Capital LP bought a new position in shares of ImageneBio during the second quarter worth about $4,611,000. Finally, Blue Owl Capital Holdings LP acquired a new stake in shares of ImageneBio in the 2nd quarter worth about $5,414,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.